| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2020: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2019: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2018: ¥7,150,000 (Direct Cost: ¥5,500,000、Indirect Cost: ¥1,650,000)
|
|---|
| Outline of Final Research Achievements |
Regular monitoring of blood drug levels at point-of-care (POC) would allow personalized drug dosage without involving centralized laboratories or the need for daily hospital visits. In this research, as a new analytical method to quantify therapeutic antibodies at POC, we developed fully integrated, rapid, low-cost, disposable and simple-to-use microfluidic thread-based analytical devices (μTADs) for bioluminescence-based antibody detection from a single drop of blood with a digital camera or a smartphone.
|
